Efficacy and safety of vedolizumab in the treatment of patients with inflammatory bowel disease: A systematic review and meta‑analysis of randomized controlled trials

Tang,Hui-Jun; Bie,Cai-Qun; Guo,Li-Liangzi; Zhong,Li-Xian; Tang,Shao-Hui

doi:10.3892/etm.2023.11997

Efficacy and safety of vedolizumab in the treatment of patients with inflammatory bowel disease: A systematic review and meta‑analysis of randomized controlled trials

Authors:
- Hui-Jun Tang
- Cai-Qun Bie
- Li-Liangzi Guo
- Li-Xian Zhong
- Shao-Hui Tang
View Affiliations

Affiliations: Department of Gastroenterology, Shenzhen Integrated Traditional Chinese and Western Medicine Hospital, Shenzhen, Guangdong 518104, P.R. China, Department of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510632, P.R. China
Published online on: May 5, 2023 https://doi.org/10.3892/etm.2023.11997
Article Number: 298
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Few studies have thoroughly assessed the efficacy and safety of vedolizumab (VDZ) in the treatment of inflammatory bowel disease (IBD). Therefore, this systematic review and meta‑analysis was performed to further evaluate this association. PubMed, Embase, and the Cochrane databases were searched until April 2022. Randomized controlled trials (RCTs) evaluating the efficacy and safety of VDZ in the treatment of IBD were included. The risk ratio (RR) and 95% confidence intervals (CI) were estimated for each outcome using a random effects model. A total of 12 RCTs, including 4,865 patients, met the inclusion criteria. In the induction phase, VDZ was more effective than placebo for patients with ulcerative colitis and Crohn's disease (CD) in clinical remission (RR=2.09; 95% CI=1.66‑2.62) and clinical response (RR=1.54; 95% CI=1.34‑1.78). In the maintenance therapy group, VDZ reached higher clinical remission (RR=1.98; 95% CI=1.58‑2.49) and clinical response (RR=1.78; 95% CI=1.40‑2.26) rates compared with the placebo group. VDZ particularly improved clinical remission (RR=2.07; 95% CI=1.48‑2.89) and clinical response (RR=1.84; 95% CI=1.54‑2.21) in patients with TNF antagonist failure. In terms of corticosteroid‑free remission, VDZ was also more effective than placebo in patients with IBD (RR=1.98; 95% CI=1.51‑2.59). In Crohn's patients, VDZ was more effective than placebo in terms of mucosal healing (RR=1.78; 95% CI=1.27‑2.51). With respect to adverse events, VDZ significantly reduced the risk of IBD exacerbation compared with the placebo (RR=0.60; 95% CI=0.39‑0.93; P=0.023). However, when compared with the placebo, VDZ increased the risk of nasopharyngitis in patients with CD (RR=1.77; 95% CI=1.01‑3.10; P=0.045). No significant differences in other adverse events were observed. Although there might be underlying risk, such as selection bias, in the present study it can be safely concluded that VDZ is a safe and effective biological agent for IBD, particularly for patients with TNF antagonist failure.

View Figures

View References

1	Seyedian SS, Nokhostin F and Malamir MD: A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 12:113–122. 2019.PubMed/NCBI View Article : Google Scholar
2	Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, et al: British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 68 (Suppl 3):s1–s106. 2019.PubMed/NCBI View Article : Google Scholar
3	Jeong DY, Kim S, Son MJ, Son CY, Kim JY, Kronbichler A, Lee KH and Shin JI: Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmun Rev. 18:439–454. 2019.PubMed/NCBI View Article : Google Scholar
4	Singh S, Fumery M, Sandborn WJ and Murad MH: Systematic review with network meta-analysis: First-and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 47:162–175. 2018.PubMed/NCBI View Article : Google Scholar
5	Wyant T, Fedyk E and Abhyankar B: An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 10:1437–1444. 2016.PubMed/NCBI View Article : Google Scholar
6	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 372(n71)2021.PubMed/NCBI View Article : Google Scholar
7	Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 343(d5928)2011.PubMed/NCBI View Article : Google Scholar
8	Chen B and Benedetti A: Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes. Syst Rev. 6(243)2017.PubMed/NCBI View Article : Google Scholar
9	Duval S and Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis,'. Biometrics. 56:455–463. 2000.PubMed/NCBI View Article : Google Scholar
10	Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, et al: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 352:2499–2507. 2005.PubMed/NCBI View Article : Google Scholar
11	Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, Ponich T, Fox I and Feagan BG: Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inﬂamm Bowel Dis. 18:1470–1479. 2012.PubMed/NCBI View Article : Google Scholar
12	Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, et al: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 369:699–710. 2013.PubMed/NCBI View Article : Google Scholar
13	Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A and Smyth M: Efﬁcacy of Vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 15:229–239.e5. 2017.PubMed/NCBI View Article : Google Scholar
14	Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, et al: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 14(e0212989)2019.PubMed/NCBI View Article : Google Scholar
15	Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, et al: Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 158:562–572.e12. 2020.PubMed/NCBI View Article : Google Scholar
16	Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Cohen A, Bitton A, Baker J, Dubé R, et al: Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 6:1370–1377. 2008.PubMed/NCBI View Article : Google Scholar
17	Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, et al: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 369:711–721. 2013.PubMed/NCBI View Article : Google Scholar
18	Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, et al: Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 147:618–627.e3. 2014.PubMed/NCBI View Article : Google Scholar
19	Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B and Lasch K: Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 23:97–106. 2017.PubMed/NCBI View Article : Google Scholar
20	Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, et al: Effects of vedolizumab in Japanese patients with Crohn's disease: A prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. J Gastroenterol. 55:291–306. 2020.PubMed/NCBI View Article : Google Scholar
21	Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Bhatia S, Agboton C, Rosario M, Chen C, et al: Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: Results from the VISIBLE 2 Randomised trial. J Crohns Colitis. 16:27–38. 2022.PubMed/NCBI View Article : Google Scholar
22	Szigethy E, McLafferty L and Goyal A: Inflammatory bowel disease. Child Adolesc Psychiatr Clin N Am. 19:301–318. ix. 2010.PubMed/NCBI View Article : Google Scholar
23	Wallace KL, Zheng LB, Kanazawa Y and Shih DQ: Immunopathology of inflammatory bowel disease. World J Gastroenterol. 20:6–21. 2014.PubMed/NCBI View Article : Google Scholar
24	Manichanh C, Borruel N, Casellas F and Guarner F: The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 9:599–608. 2012.PubMed/NCBI View Article : Google Scholar
25	Latella G and Papi C: Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol. 18:3790–3799. 2012.PubMed/NCBI View Article : Google Scholar
26	Xu XR, Liu CQ, Feng BS and Liu ZJ: Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 20:3255–3264. 2014.PubMed/NCBI View Article : Google Scholar
27	Rosen MJ, Dhawan A and Saeed SA: Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 169:1053–1060. 2015.PubMed/NCBI View Article : Google Scholar
28	Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et al: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 390:2769–2778. 2017.PubMed/NCBI View Article : Google Scholar
29	Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG and Long MD: ACG clinical guideline: Ulcerative colitis in adults. Am J Gastroenterol. 114:384–413. 2019.PubMed/NCBI View Article : Google Scholar
30	Hering NA and Schulzke JD: Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig Dis. 27:450–454. 2009.PubMed/NCBI View Article : Google Scholar
31	Strik AS, Bots SJ, D'Haens G and Löwenberg M: Optimization of anti-TNF therapy in patients with inflammatory bowel disease. Expert Rev Clin Pharmacol. 9:429–439. 2016.PubMed/NCBI View Article : Google Scholar
32	Ben-Horin S and Chowers Y: Tailoring anti-TNF therapy in IBD: Drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 11:243–255. 2014.PubMed/NCBI View Article : Google Scholar
33	Ben-Horin S and Chowers Y: Review article: Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 33:987–995. 2011.PubMed/NCBI View Article : Google Scholar
34	Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA and Sinha S: Anti-Integrins for the treatment of inflammatory bowel disease: Current evidence and perspectives. Clin Exp Gastroenterol. 14:333–342. 2021.PubMed/NCBI View Article : Google Scholar
35	Hemler ME, Huang C, Takada Y, Schwarz L, Strominger JL and Clabby ML: Characterization of the cell surface heterodimer VLA-4 and related peptides. J Biol Chem. 262:11478–11485. 1987.PubMed/NCBI
36	Lanzarotto F, Carpani M, Chaudhary R and Ghosh S: Novel treatment options for inflammatory bowel disease: Targeting alpha 4 integrin. Drugs. 66:1179–1189. 2006.PubMed/NCBI View Article : Google Scholar
37	Soler D, Chapman T, Yang LL, Wyant T, Egan R and Fedyk ER: The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 330:864–875. 2009.PubMed/NCBI View Article : Google Scholar
38	Amiot A, Bouguen G, Bonnaud G, Bouhnik Y, Hagege H and Peyrin-Biroulet L: French National Consensus Clinical guidelines for the management of IBD study group. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. Dig Liver Dis. 53:35–43. 2021.PubMed/NCBI View Article : Google Scholar
39	Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW and Kaplan GG: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 142:46–54 e42. 2012.PubMed/NCBI View Article : Google Scholar
40	Ye Y, Manne S, Treem WR and Bennett D: Prevalence of inflammatory bowel disease in pediatric and adult populations: Recent estimates from large national databases in the United States,2007-2016. Inflamm Bowel Dis. 26:619–625. 2020.PubMed/NCBI View Article : Google Scholar
41	Wang MC, Zhang LY, Han W, Shao Y, Chen M, Ni R, Wang GN, Wei FX, Zhang YW, Xu XD and Zhang YC: PRISMA-efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 93(e326)2014.PubMed/NCBI View Article : Google Scholar
42	Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM and Loftus EV Jr: Systematic review with meta-analysis: Real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 53:1048–1064. 2018.PubMed/NCBI View Article : Google Scholar
43	Mosli MH, MacDonald JK, Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, Khanna R and Feagan BG: Vedolizumab for induction and maintenance of remission in ulcerative colitis: A Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 21:1151–1159. 2015.PubMed/NCBI View Article : Google Scholar